Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

by | May 20, 2026 | Clinical Trials | 0 comments

​ Conditions: Pneumococcal Vaccines

Interventions: Biological: 31-valent pneumococcal conjugate vaccine; Biological: PCV20

Sponsors: Vaxcyte, Inc.

Recruiting Conditions: Pneumococcal Vaccines
Interventions: Biological: 31-valent pneumococcal conjugate vaccine; Biological: PCV20
Sponsors: Vaxcyte, Inc.
Recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *